Hospital Universitario Rio Hortega

Research in Hematología at this Hospital/Clinic centers on hemic and lymphatic diseases, with studies focused on acute myeloid leukemia, hemophilia A, and other blood-related conditions. These trials are designed to test new treatment approaches, improve disease control, and evaluate longer-term safety and effectiveness.

• New therapies for acute myeloid leukemia are being assessed to improve survival outcomes and treatment response.
• Studies in hemophilia A are exploring advanced options to strengthen bleeding control and patient safety.
• Additional work covers broader hematologic disorders to refine supportive care and treatment strategies.

The site’s activity in blood diseases reflects a strong interest in both innovative therapies and practical improvements in care for patients with complex hematologic conditions.

A major part of the trial portfolio addresses immune system diseases and autoimmune disorders, especially systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, and idiopathic inflammatory myopathies. The studies aim to reduce disease activity, improve symptom control, and assess the safety of emerging treatments.

• Multiple trials are evaluating new options for systemic lupus erythematosus and related skin and kidney involvement.
• Research also includes lupus nephritis, dermatomyositis, and myositis to address difficult-to-treat immune conditions.
• Studies in rheumatoid arthritis and other inflammatory diseases are focused on better disease control and tolerability.

This area highlights a strong commitment to autoimmune research, with the goal of identifying therapies that can offer more durable benefit for patients with chronic inflammatory disease.

The site is also active in digestive system diseases and liver disorders, including Crohn's disease, ulcerative colitis, primary biliary cholangitis, primary sclerosing cholangitis, and eosinophilic esophagitis. These trials are mainly testing new treatments and comparing strategies to improve disease remission and long-term control.

• Inflammatory bowel disease studies focus on Crohn's disease and ulcerative colitis, with an emphasis on remission and prevention of relapse.
• Liver-related research includes primary biliary cholangitis and primary sclerosing cholangitis to evaluate better disease management.
• Additional work in eosinophilic esophagitis aims to improve treatment effectiveness for esophageal inflammation.

Overall, this research stream combines gastroenterology and hepatology to advance care for patients with chronic inflammatory and autoimmune digestive diseases.

Cancer studies at Hospital Universitario Rio Hortega cover neoplasms such as acute myeloid leukemia, colon cancer, pancreatic adenocarcinoma, and non-muscle invasive bladder cancer. The trials are aimed at improving survival, reducing recurrence, and comparing new treatment combinations with standard care.

• Research in colorectal cancer and pancreatic cancer is examining ways to improve post-surgical outcomes and disease-free survival.
• Studies in bladder cancer are evaluating whether new adjuvant approaches can better control high-risk disease.
• Hematologic oncology work includes trials in acute myeloid leukemia to explore more effective treatment options.

This oncology portfolio reflects a broad effort to strengthen cancer treatment across both solid tumors and blood cancers.

Another important research area involves cardiovascular diseases, hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, and pulmonary embolism. These trials are designed to test better ways to reduce major cardiovascular events, improve blood pressure control, and support patients with overlapping metabolic risk.

• Studies in hypertension are exploring improved control for patients with difficult-to-manage blood pressure.
• Trials in type 2 diabetes and cardiovascular disease are evaluating treatments that may lower future heart-related risk.
• Research on pulmonary embolism is focused on safer and more effective treatment for acute clot-related illness.

This area links metabolism and heart health, reflecting the site’s interest in conditions that often occur together and require long-term management.

The site participates in trials on respiratory tract diseases, critical condition, and septic shock, including work in chronic obstructive pulmonary disease, acute hypoxemic respiratory failure, and bronchiectasis. These studies assess treatment effectiveness, symptom control, and approaches that may improve outcomes in seriously ill patients.

• In COPD and bronchiectasis, research is focused on better control of chronic breathing problems.
• Acute care studies address respiratory failure and septic shock to improve survival and recovery.
• The research also includes supportive care questions in critical illness, such as optimizing hospital outcomes.

This portfolio shows a clear focus on pulmonary medicine and intensive care, with the aim of improving care in both chronic and emergency settings.

Clinical trials at the site also address eye diseases, nervous system diseases, and mental disorders, including neovascular age-related macular degeneration, geographic atrophy, Alzheimer’s disease-related agitation, and psychosis. These studies are mainly testing new therapies and evaluating how well they control symptoms over time.

• Ophthalmology research is focused on age-related macular degeneration and related retinal conditions to preserve vision.
• Neuropsychiatric studies explore treatments for agitation and psychosis linked to Alzheimer’s disease.
• These trials aim to improve quality of life by easing symptoms and supporting daily function.

This mix of ophthalmology, neurology, and psychiatry shows a wide-ranging interest in conditions that affect both function and independence.